PDCD1 and non-small cell lung carcinoma: Additionally, it is currently being tested in phase II/III trial for metastatic and recurrent head and neck cancer (HNSCC) and phase I/II for non-small cell lung cancer (NSCLC) with another PD1 inhibitor, Pembrolizumab (NCT02989714, NCT03138889).